Compare IDEXX Laboratories, Inc. (IDXX) vs TKO Group Holdings Inc (TKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs TKO Group Holdings Inc — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while TKO Group Holdings Inc trades at $179 (market cap $13.28B). The key difference: IDEXX Laboratories, Inc. is far larger — about 3× TKO Group Holdings Inc's market cap, and TKO Group Holdings Inc pays a 1.74% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and TKO Group Holdings Inc for 30 Days on average.
| IDXX | TKO | |
|---|---|---|
Market Cap | $40.43B | $13.28B |
Volume | 692,164 | 857,653 |
Sector | Health | Media |
52-Week High | $766.68 | $224.96 |
52-Week Low | $504.70 | $175.58 |
Typical Hold Time | 46 Days | 30 Days |
Enterprise Value | $41.32B | $17.64B |
Dividend Yield | — | 1.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $518.00, up 2.24% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and product expansions highlight growth initiatives. Analyst consensus remains bullish with a $665 price target, though technical indicators suggest near-term caution.
Outlook remains positive driven by diagnostic innovation and recurring revenue growth, but faces headwinds from FX volatility and weaker U.S. vet visits. The 36.06 P/E ratio reflects premium valuation, requiring sustained execution. Risks include competitive pressures and insider selling, while institutional ownership trends show mixed signals.
TKO trades at $178.01, down 0.35% on the day, near its 52-week low of $174.58 (Defense World, 2026-10-02). The stock is technically bearish with mixed earnings history, including a Q2 2026 EPS miss. Revenue grew to $5.3B in 2026 with a net profit margin of 4.32%. A quarterly dividend of $0.79 is scheduled for payment on September 30, 2026.
Wall Street maintains a strong buy consensus (89% buy ratings) with a $227 price target, suggesting significant upside. Key risks include earnings volatility and competitive pressures in sports entertainment. Positive catalysts are media rights deals and live event momentum, but the stock faces near-term technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →
